Sarepta Therapeutics: Q4 Earnings Snapshot

SelfRugger · 2026-03-27T15:34:50+00:00

Sarepta Therapeutics reported a fourth-quarter loss of $412.2 million, or $3.93 per share, missing Wall Street expectations. However, revenue for the quarter was $442.9 million, surpassing forecasts. The annual loss totaled $713.4 million.

SelfRugger

2026-03-27 15:34:50

Abstract generation in progress

Sarepta Therapeutics: Q4 Earnings Snapshot

Associated Press Finance

Thu, February 26, 2026 at 6:40 AM GMT+9 1 min read

In this article:

SRPT

+0.69%

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Sarepta Therapeutics Inc. (SRPT) on Wednesday reported a loss of $412.2 million in its fourth quarter.

On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $3.93. Losses, adjusted for stock option expense and non-recurring costs, were $3.58 per share.

The results missed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 71 cents per share.

The biopharmaceutical company posted revenue of $442.9 million in the period, exceeding Street forecasts. Nine analysts surveyed by Zacks expected $408.5 million.

For the year, the company reported a loss of $713.4 million, or $7.13 per share. Revenue was reported as $2.2 billion.

This story was generated by Automated Insights () using data from Zacks Investment Research. Access a Zacks stock report on SRPT at

Terms and Privacy Policy

Privacy Dashboard

More Info

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes